Potassium paraaminobenzoate vs placebo
Treatment‐related adverse effects · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.27 [0.36, 4.48]1 study · 103 participantsVery low